

## Datasheet: MCA1037GA

**BATCH NUMBER 163037**

<b>Description:</b>	RAT ANTI DOG CD5
<b>Specificity:</b>	CD5
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	YKIX322.3
<b>Isotype:</b>	IgG2a
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/50 - 1/100
Immunohistology - Frozen	▪			
Immunohistology - Paraffin			▪	
ELISA			▪	
Immunoprecipitation	▪			
Western Blotting			▪	

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Dog
<b>Product Form</b>	Purified IgG - liquid
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Carrier Free</b>	Yes

<b>Approx. Protein Concentrations</b>	IgG concentration 1.0 mg/ml
<b>Immunogen</b>	Concanavilin A activated canine peripheral blood cells
<b>Fusion Partners</b>	Spleen cells from an immunised DA rat were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line
<b>Specificity</b>	<p><b>Rat anti Dog CD5 antibody, clone YKIX322.3</b> recognizes canine CD5, a 67 kDa cell surface type 1 transmembrane glycoprotein also known as lymphocyte antigen T1, Ly-1 or Leu-1. CD5 is expressed on the surface of T-cells and thymocytes, CD5 is also expressed by NK cells at low levels (<a href="#">Huang et al. 2008</a>). Rat anti dog CD5, clone YKIX322.3 was clustered as canine CD5 in the First Canine Leucocyte Antigen Workshop (<a href="#">Cobbold et al. 1994</a>).</p> <p>In a study of 73 cases of canine chronic lymphocytic leukemia (CLL) CD5 expression was absent on all cases of B-cell CLL as defined by CD21 expression and lack of CD3 or other T cell antigen expression (<a href="#">Vernau and Moore 1999</a>). Rat anti dog CD5 serves as a useful marker for the discrimination of canine leukemias of differing origins (<a href="#">Deravi et al. 2017</a>).</p>
<b>Flow Cytometry</b>	Use 10ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul.
<b>References</b>	<ol style="list-style-type: none"> <li>Cobbold, S/ &amp; Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). <a href="#">Tissue Antigens. 43 (3): 137-54.</a></li> <li>Hewicker-Trautwein, M. et al. (1999) Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease. <a href="#">Vet Immunol Immunopathol. 67 (4): 341-57.</a></li> <li>Huang, Y.C. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. <a href="#">J Leukoc Biol. 84: 1501-10.</a></li> <li>Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. <a href="#">Vet Immunol Immunopathol. 141: 64-75.</a></li> <li>Burnett, R.C. et al. (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. <a href="#">Vet Pathol. 40: 32-41.</a></li> <li>Fosmire, S.P. et al. (2007) Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. <a href="#">Vet Pathol. 44: 467-78.</a></li> <li>Guarga, J.L. et al. (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. <a href="#">Vet Immunol Immunopathol. 88: 13-20.</a></li> <li>Vernau, W. Moore, P.F. et al. (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. <a href="#">Vet Immunol Immunopathol. 69: 145-64.</a></li> <li>Lamerato-kozicki, A.R. et al. (2006) Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. <a href="#">Exp Hematol. 34 (7): 870-8.</a></li> <li>Rütgen BC et al. (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. <a href="#">PLoS One.</a></li> </ol>

[7 \(6\): e40078.](#)

11. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. [Vet Comp Oncol. 12: 29-36.](#)
12. Moreira, M.L. *et al.* (2016) Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes. [Vet Parasitol. 220: 33-45.](#)
13. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. [Vet Immunol Immunopathol. 159 \(1-2\): 91-6.](#)
14. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. [Vet Immunol Immunopathol. 155 \(3\): 211-7.](#)
15. Karayannopoulou, M. *et al.* (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. [Vet Immunol Immunopathol. 186: 45-50.](#)
16. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
17. Gibbons, N. *et al.* (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs. [Vet Immunol Immunopathol. 190: 26-30.](#)
18. Deravi, N. *et al.* (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes. [Vet Immunol Immunopathol. 191: 5-13.](#)
19. GomesMde, O. *et al.* (2011) Old beagle dogs have lower faecal concentrations of some fermentation products and lower peripheral lymphocyte counts than young adult beagles. [Br J Nutr. 106 Suppl 1: S187-90.](#)
20. MariaA, P.J. *et al.* (2017) The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs. [J Anim Sci. 95 \(6\): 2452-66.](#)
21. Stokol, T. *et al.* (2015) Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. [Vet Clin Pathol. 44 \(1\): 79-93.](#)
22. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. [Res Vet Sci. 125: 130-5.](#)
23. Lin, C.S. *et al.* (2018) Activating natural killer (NK) cytotoxicity of canine CD5<sup>+</sup>CD21<sup>-</sup> cells requires low surface CD5 density NK cells. [Iran J Vet Res. 19 \(2\): 87-95.](#)
24. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. [Front Immunol. 8: 217.](#)
25. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. [BMC Vet Res. 9: 94.](#)
26. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune<sup>®</sup>, and Leish-Tec<sup>®</sup> Vaccines against Canine Visceral Leishmaniasis. [Vaccines \(Basel\). 8 \(4\)Nov 17 \[Epub ahead of print\].](#)
27. Graves, S.S. *et al.* (2019) Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. [Vet Immunol Immunopathol. 211: 10-8.](#)
28. Ito, D. *et al.* (2015) A double blinded, placebo-controlled pilot study to examine reduction of CD34<sup>+</sup>/CD117<sup>+</sup>/CD133<sup>+</sup> lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.

[F1000Res. 4: 42.](#)

29. Wolf-Ringwall, A. *et al.* (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. [Vet Comp Oncol. 18 \(3\): 342-52.](#)
30. Sayag, D. *et al.* (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma. [Vet Clin Pathol. 49 \(3\): 476-83.](#)
31. Lee, J. *et al.* (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. [Biomed Res Int. 2021: 6690704.](#)
32. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. [Vet Comp Oncol. 19 \(3\): 567-77.](#)
33. Lee, S.H. *et al.* (2021) Safety and immunological effects of recombinant canine IL-15 in dogs. [Cytokine. 148: 155599.](#)
34. Karayannopoulou, M. *et al.* (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer [Vet Immunol Immunopathol. 24 Feb: 110403.](#)
35. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. [J Immunother Cancer. 10 \(5\): e004007. \[Epub ahead of print\].](#)
36. Jaensch, S. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia [Australian Veterinary Journal. \[Epub ahead of print\].](#)

---

<b>Storage</b>	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.  Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
<b>Guarantee</b>	12 months from date of despatch
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10040 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1037GA">https://www.bio-rad-antibodies.com/SDS/MCA1037GA</a> 10040
<b>Regulatory</b>	For research purposes only

---

## Related Products

### Recommended Secondary Antibodies

Goat Anti Rat IgG (STAR69...)	<a href="#">FITC</a>
Goat Anti Rat IgG (STAR73...)	<a href="#">RPE</a>
Goat Anti Rat IgG (MOUSE ADSORBED) (STAR71...)	<a href="#">DyLight®550</a> , <a href="#">DyLight®650</a> , <a href="#">DyLight®800</a>
Rabbit Anti Rat IgG (STAR21...)	<a href="#">HRP</a>
Rabbit Anti Rat IgG (STAR16...)	<a href="#">DyLight®800</a>
Goat Anti Rat IgG (STAR131...)	<a href="#">Alk. Phos.</a> , <a href="#">Biotin</a>
Rabbit Anti Rat IgG (STAR17...)	<a href="#">FITC</a>

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M382457:210513'

**Printed on 12 Aug 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)